Previous studies have shown that NDEV biomarkers, including Aβ42, p-Tau and total Tau, can accurately discriminate between individuals with clinical AD and controls, predict future AD diagnosis at the preclinical stage, and predict conversion from MCI to AD dementia and future cognitive decline among individuals at higher genetic risk for the disease [13,15,17]. The gene discussed is MAPT; the disease is Alzheimer disease.